ANI Pharmaceuticals: Record Quarter, Cortrophin Guidance Cut — Buy the Cheap Multiple

ANI Pharmaceuticals (NASDAQ: ANIP) reported record second-quarter results on August 7, then quietly lowered the ceiling on its growth engine for the rest of the year. Revenue topped consensus, earnings beat, and Cortrophin Gel grew 43.5%. And yet management trimmed the full-year Cortrophin Gel revenue midpoint by roughly $28 million, from $558 million to $530 million. The stock rose 3.4% on the release, trading at $82.63. The market gave the quarter a pass. That reaction makes sense only if the valuation already discounts what might be slowing in the second half — and at these multiples, it does.

What the quarter showed

Total revenue hit $266 million, up 25.9% year-over-year and ahead of the consensus estimate of $260 million. Adjusted EPS came in at $2.21 versus the $2.04 estimate — an 8% beat. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization — a rough proxy for cash earnings) surged 32.4% to $71.6 million.

The growth engine was, again, Cortrophin Gel. At $117.1 million for the quarter, it grew 43.5% from $81.6 million a year ago. Cortrophin is ANI's purified ACTH (adrenocorticotropic hormone) therapy, approved for rare endocrine conditions in nephrology, neurology, ophthalmology, pulmonology, and rheumatology. It carries a specialty drug price tag, a protected approval profile, and the kind of revenue acceleration that explains why ANI has been pivoting its identity away from generics.

Rare disease revenue — Cortrophin plus ILUVIEN and other specialty assets — reached $135.8 million, up 30.7%. That represents 51% of total revenue. Six months ago it was closer to 45%. The shift toward higher-margin specialty products is structural, not seasonal.

Generics, meanwhile, grew a modest 9.7% to $100.7 million. ANI has launched 12 new generic products year-to-date and expects at least 15 in 2026. That is a functional business, but not the one driving valuation expansion. It also carries the risk that comes with the space: competitive erosion and pricing pressure from new entrants.

The guidance cut: why it matters more than the headline

The market-friendly headline was the record quarter. The less-celebrated line item is the Cortrophin Gel guidance adjustment. ANI brought the full-year range down from $540 million–$575 million to $520 million–$540 million. On a prior-year Cortrophin base of $348 million, the new midpoint still implies 52% full-year growth. That is fast. But the previous range implied 57–65% growth. Management chose to come off the high side of that band.

CEO Nikhil Lalwani cited a "solid track record of commercial execution and prudent capital allocation" as the basis for the revised outlook. In plain language: the first half was so strong that projecting the same pace into H2 felt overextended. The gout expansion — now fully operational as of June — accounts for the near-term excitement but has not yet been tested across a full business cycle. ANI targets an addressable market of roughly 285,000 gout patients, reaching podiatrists and primary care physicians. Over 95% of reps generated multiple new patient cases in their first run. The early adoption data is convincing, but the guidance cut signals management does not expect H2 gout uptake to match the ramp trajectory of existing specialty areas.

Full-year revenue guidance at $1.08 billion–$1.14 billion and adjusted EBITDA at $285 million–$300 million were both reaffirmed. That is important. The Cortrophin cut is absorbed elsewhere — likely in stronger-than-expected generics performance or royalty and milestone revenue. ANI took in $9.7 million from its Harmony Agreement (pitolisant royalties) and $8 million in development milestone fees, with another $2 million milestone expected in Q3.

The net effect: the quarter is a beat with a speed bump in the middle of the road, not a crash.

Margin dynamics

Gross margin declined to 62.4% (GAAP) from 64.7% a year ago. This is a mix story, not a cost problem. Cortrophin Gel and a partnered generic carry royalty obligations, and ANI no longer has the prior-year Prucalopride revenue that carried thicker margins. The royalty drag grows as Cortrophin's share of the top line expands. Full-year gross margin guidance is 59.9%–60.9%, below the TTM level of 60.8%.

That said, operating leverage is still working. Adjusted EBITDA margins sit at roughly 27% on a quarterly run rate, and full-year guidance implies roughly 26–26.3%. Free cash flow margins have been extraordinary: 19.8% trailing twelve months, with FCF surging 277% year-over-year to $182.8 million. At the current market cap of $1.88 billion, that translates to a free cash flow yield of roughly 9.7%.

Valuation: cheap enough to buy the Cortrophin uncertainty

Here is the core question: has the market mispriced the next operating phase?

ANI trades at roughly 8.8 times forward earnings using the midpoint of its $9.19–$9.69 adjusted EPS guidance. The trailing P/E is 20.6x, but the forward multiple tells the real story for a company still accelerating. On a TTM basis, the stock sits at 17.8x EV/EBITDA and 2.0x sales. On a guided EBITDA run rate of roughly $300 million, the enterprise value of $2.17 billion works out to approximately 7.2x — well below 9x 2026 adjusted EBITDA, implying roughly 30% upside.

For comparison, Amneal Pharmaceuticals (NASDAQ: AMRX) — a larger generics-heavy peer that grew revenue just 9.9% last quarter — trades at 47x trailing earnings. Amneal gets the higher multiple on its market cap (nearly $5.8 billion versus ANI's $1.9 billion) despite materially slower growth. ANI is being valued like a generics company while half its revenue now comes from specialty rare disease products with 43% growth rates and protected approval status.

The PEG ratio (forward P/E divided by expected growth) works out to roughly 0.17. That means investors are paying less than 17 cents of forward multiple for each percentage point of expected earnings growth. For context, PEG ratios above 1.0 are often considered "fair" in growth stocks; below 0.5 is territory usually reserved for either extreme bargain or hidden structural risk.

The cheap multiple is the bridge that makes the Cortrophin guidance cut acceptable. If ANI were trading at 20x forward earnings, that $28 million midpoint reduction would be a problem. At 8.8x, it is already priced in.

Balance sheet and buyback

The balance sheet is the one area requiring scrutiny. Total debt stands at $860 million against $311 million in cash, for net debt of roughly $288 million. Debt-to-equity is 109%, which is elevated but manageable given the free cash flow profile. With $183 million in trailing FCF, net debt is roughly 1.6x cash flow — not dangerously leveraged for a company of this scale and growth trajectory.

The board authorized a fresh $100 million share repurchase program through May 2029. At current prices and 21.8 million diluted shares outstanding, that buyback capacity represents roughly 2.4% of market cap. It is modest but directionally supportive.

Risks

Three factors could break the thesis:

• Cortrophin growth deceleration beyond the guidance cut. The new range still implies 50–55% full-year growth. If gout uptake stalls or competitive pressure enters existing specialty channels, H3 and H4 could fall short even of the lowered bar.
• Generics exposure. Roughly half of ANI's revenue still comes from generics, a business segment defined by competitive erosion and pricing declines. The 9.7% generics growth this quarter is solid, but the trajectory is inherently downward over time.
• Gross margin compression. The royalty burden on Cortrophin and the loss of Prucalopride revenue are structural headwinds, not temporary blips. If gross margin drifts below the 59.9% floor of the guidance range, EBITDA expansion becomes harder to sustain.

ILUVIEN's decline of 16.1% to $18.7 million is less concerning — management attributed it to international shipment timing — but it remains a drag on the rare disease segment until the SYNCHRONICITY Phase 4 trial results (expected Q4 2026) provide a new catalyst.

Investor takeaway

Rating: Buy.

ANI Pharmaceuticals delivered a quarter that confirms its rare disease transition is real — 51% of revenue now comes from specialty products growing in the low- to mid-40s. The Cortrophin guidance cut tempers the enthusiasm but does not undermine the trajectory: the new midpoint still projects over 50% annual growth. What matters most is that the stock trades at 8.8x forward earnings with a 9.7% free cash flow yield. The market is still pricing ANI like a generics company, not the hybrid specialty-generics business it has become.

The next proof point is Q3 earnings, scheduled for late November. Investors should watch three things: whether Cortrophin Gel maintains its growth pace into the second half, whether gout expansion continues to generate multi-case prescribing across the sales force, and whether gross margin holds above the 60% floor. If those hold, the current valuation offers substantial upside. If Cortrophin decelerates below the new guidance band, the cheap multiple still provides a cushion — but the upgrade case narrows.

At 8.8x forward earnings on a company growing revenue in the low-20s and earnings in the high-teens, ANI is too cheap to ignore.